Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial
A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), ...
Tag: First-Line NSCLC Therapy** **Kısa Açıklama:** 1. **EGFR-Mutant NSCLC:** Makalenin odaklandığı temel kanser türü ve alt grubu. 2. **MET Aberrations:** Çalışman
